register

News & Trends - Pharmaceuticals

Melanoma specialist deems new PBS listing ‘particularly significant’

Health Industry Hub | January 22, 2024 |

Pharma News: Australians battling unresectable or metastatic melanoma will soon have access to a pioneering immunotherapy treatment, as Bristol-Myers Squibb’s Opdualag (nivolumab/relatlimab) is set to be listed on the Pharmaceutical Benefits Scheme (PBS) starting February 1, 2024.

The listing comes as part of the PBS reimbursements since 1st January, which has already provided Australians access to affordable and innovative therapies for advanced ovarian cancer (Lynparza), chronic lymphocytic leukaemia and small lymphocytic lymphoma (Calquence), cystic fibrosis (Orkambi), and atypical haemolytic uraemic syndrome (aHUS) (Ultomiris).

Opdualag represents Australia’s first combined anti-PD-1/anti-LAG-3 treatment for patients aged 12 years or older dealing with unresectable or metastatic melanoma. This combination therapy, a fixed-dose combination of nivolumab (PD-1 inhibitor) and relatlimab (LAG-3-blocking antibody), holds promise in restoring the effector function of exhausted T-cells and promoting antitumour activity.

The decision to include Opdualag in the PBS was substantiated by the compelling clinical trial data from the Phase 2/3 RELATIVITY-047 study. In patients with treatment-naïve unresectable Stage III or metastatic melanoma, Opdualag more than doubled the median progression-free survival (PFS) compared to nivolumab alone. At a median follow-up of 13.2 months, the combination demonstrated a PFS of 10.1 months, compared to 4.6 months with nivolumab alone (p=0.006).

Co-Medical Director of Melanoma Institute Australia and 2024 NSW Australian of the Year, Professor Georgina Long, AO, expressed the significance of this approval in the realm of melanoma treatment. Despite notable progress in the past decade, Professor Long emphasised the need for more treatment options to enhance patient outcomes.

“This approval is particularly significant, as it shows commitment and focus on bringing innovative drug therapy options to patients, and targeting two different immune checkpoints — LAG-3 and PD-1 – does just that,” said Professor Long

Founder and Director of the Melanoma & Skin Cancer Advocacy Network (MSCAN), Tamara Dawson, welcomed the reimbursement of Opdualag, emphasising the importance of affordable treatment options. While advancements have been made in treating advanced melanoma, the addition of a new combination immunotherapy treatment to the PBS is a welcome development for Australians grappling with the disease.

Dr Melinda Munns, Medical Director for Bristol-Myers Squibb Australia and New Zealand, echoed these sentiments, underlining the commitment to expanding dual immunotherapy treatment options.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.